Drug Trial Radar · NCT06290102
Pharmacokinetic Profile and Safety of Fluticasone Propionate and Albuterol Sulfate in Combination When Compared to Fluticasone Propionate Multidose Dry Powder Inhaler (Fp MDPI) in Children Aged 4 to 11 Years Old
Last checked: Nov 19, 2026Latest source record: Aug 4, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
30
Actual
Start
May 16, 2024
Primary completion
Oct 1, 2024
Study completion Oct 7, 2024
Sponsor
- Lead sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.Teva (TEVA)
- Sponsor type
- Industry
- First posted
- Mar 4, 2024
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Crossover
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 4 years, up to 11 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The primary objectives of this study are: * To determine the pharmacokinetic (PK) profile of fluticasone propionate (Fp) and albuterol sulfate (ABS), delivered in combination, from a single dose of TEV-56248 (Fp and ABS multidose dry powder inhaler with e-module \[Fp/ABS eMDPI\]) in participants with asthma * To compare the PK profiles of Fp for 2 different dose strengths of TEV-56248 to that of fluticasone propionate multidose dry powder inhaler (Fp MDPI) * To compare the PK profiles of ABS between the 2 different strengths of TEV-56248 The secondary objective is: • To evaluate the safety of a single dose of TEV-56248 and a single dose of Fp MDPI
Conditions
- Asthma
Interventions
TEV-56248Drug
Pharmaceutical form: Dry powder Route of administration: Oral inhalation
Fp MDPIDrug
Pharmaceutical form: Dry powder Route of administration: Oral inhalation
Primary outcomes
What the sponsor says the trial is designed to measure.
- Maximum Observed Plasma Drug Concentration (Cmax) of Fluticasone Propionate (Fp)Time frame: Up to 24 hours postdose
- Maximum Observed Plasma Drug Concentration (Cmax) of Albuterol Sulfate(ABS)Time frame: Up to 24 hours postdose
- Area Under the Plasma Drug Concentration-Time Curve from Time 0 to the Time of the Last Measurable Drug Concentration (AUC0-t) for FpTime frame: Up to 24 hours postdose
- Area Under the Plasma Drug Concentration-Time Curve from Time 0 to the Time of the Last Measurable Drug Concentration (AUC0-t) for ABSTime frame: Up to 24 hours postdose
- Area Under the Plasma Drug Concentration-Time Curve from Time 0 to 24 Hours Postdose (AUC0-24) of Fluticasone PropionateTime frame: Up to 24 hours postdose
- AUC0-24 of Albuterol SulfateTime frame: Up to 24 hours postdose
- Time to Maximum Observed Plasma Drug Concentration (tmax) for FpTime frame: Up to 24 hours postdose
- Time to Maximum Observed Plasma Drug Concentration (tmax) for ABSTime frame: Up to 24 hours postdose
- Terminal Phase (Apparent Elimination) Half-Life (t½) of FpTime frame: Up to 24 hours postdose
- Terminal Phase (Apparent Elimination) Half-Life (t½) of ABSTime frame: Up to 24 hours postdose
- Last Measurable Concentration Above the Quantification Limit (Clast) of FpTime frame: Up to 24 hours postdose
- Last Measurable Concentration Above the Quantification Limit (Clast) of ABSTime frame: Up to 24 hours postdose
- Time of Last Measurable Concentration (tlast) of FpTime frame: Up to 24 hours postdose
- Time of Last Measurable Concentration (tlast) of ABSTime frame: Up to 24 hours postdose
Locations
10 sites in 1 country. Site status is shown where the registry gives one.
Teva Investigational Site 12010
Mobile, Alabama
Teva Investigational Site 12003
Long Beach, California
Teva Investigational Site 12007
Miami, Florida
Teva Investigational Site 12005
Miami, Florida
Teva Investigational Site 12002
Miami, Florida
Teva Investigational Site 12008
Lafayette, Louisiana
Teva Investigational Site 12011
Columbia, Missouri
Teva Investigational Site 12012
Oklahoma City, Oklahoma
Teva Investigational Site 12001
Boerne, Texas
Teva Investigational Site 12009
San Antonio, Texas
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.